KR20090064378A - 유방암 관련 유전자 및 폴리펩티드 - Google Patents

유방암 관련 유전자 및 폴리펩티드 Download PDF

Info

Publication number
KR20090064378A
KR20090064378A KR1020097004837A KR20097004837A KR20090064378A KR 20090064378 A KR20090064378 A KR 20090064378A KR 1020097004837 A KR1020097004837 A KR 1020097004837A KR 20097004837 A KR20097004837 A KR 20097004837A KR 20090064378 A KR20090064378 A KR 20090064378A
Authority
KR
South Korea
Prior art keywords
seq
polypeptide
amino acid
acid sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097004837A
Other languages
English (en)
Korean (ko)
Inventor
유스케 나카무라
토요마사 가타기리
슈이치 나카츠루
Original Assignee
온코세라피 사이언스 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코세라피 사이언스 가부시키가이샤 filed Critical 온코세라피 사이언스 가부시키가이샤
Publication of KR20090064378A publication Critical patent/KR20090064378A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
KR1020097004837A 2006-08-10 2007-08-10 유방암 관련 유전자 및 폴리펩티드 Withdrawn KR20090064378A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US83742806P 2006-08-10 2006-08-10
US60/837,428 2006-08-10
US84025006P 2006-08-25 2006-08-25
US60/840,250 2006-08-25
US91502207P 2007-04-30 2007-04-30
US60/915,022 2007-04-30

Publications (1)

Publication Number Publication Date
KR20090064378A true KR20090064378A (ko) 2009-06-18

Family

ID=38627000

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097004837A Withdrawn KR20090064378A (ko) 2006-08-10 2007-08-10 유방암 관련 유전자 및 폴리펩티드

Country Status (8)

Country Link
US (2) US8673548B2 (https=)
EP (1) EP2057187B1 (https=)
JP (1) JP5339291B2 (https=)
KR (1) KR20090064378A (https=)
BR (1) BRPI0716498A2 (https=)
CA (1) CA2660438A1 (https=)
SG (1) SG174071A1 (https=)
WO (1) WO2008018642A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005029067A2 (en) 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing breast cancer
KR20080052570A (ko) 2005-07-29 2008-06-11 타게티드 그로스 인코퍼레이티드 야생형 ｋｒｐ에 의한 활성 사이클린-ｃｄｋ 복합체 억제의우성 음성 돌연변이 ｋｒｐ 단백질 보호
JP5514453B2 (ja) * 2008-03-04 2014-06-04 株式会社キノファーマ 発光タンパク質を用いたリン酸化酵素阻害物質のスクリーニング方法
EP2275567A1 (en) * 2009-07-15 2011-01-19 Rheinische Friedrich-Wilhelms-Universität Bonn Nucleic acid expression construct and its use as a cell proliferation marker
EP2542155B1 (en) * 2010-03-01 2015-11-04 TAU Therapeutics LLC Method for imaging a disease
US20120131698A1 (en) * 2010-11-12 2012-05-24 Targetd Growth, Inc. Dominant Negative Mutant Kip-Related Proteins (KRP) in Zea Mays and Methods of Their Use
CA2867139A1 (en) 2011-04-11 2012-10-18 Targeted Growth, Inc. Identification and the use of krp mutants in plants
US9062323B2 (en) 2011-04-11 2015-06-23 The Regents Of The University Of California Identification and use of KRP mutants in wheat
JP6014904B2 (ja) * 2011-07-29 2016-10-26 国立大学法人徳島大学 Ｅｒａｐ１由来ペプチド及びその使用
CN104066746B (zh) * 2011-10-28 2017-12-05 肿瘤疗法科学股份有限公司 Topk肽及包含它们的疫苗
JP6112569B2 (ja) 2011-12-16 2017-04-12 国立大学法人 東京医科歯科大学 キメラ２重鎖核酸
GB201121924D0 (en) * 2011-12-20 2012-02-01 Fahy Gurteen Labs Ltd Detection of breast cancer
US9903871B2 (en) 2014-07-15 2018-02-27 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from nucleoredoxin X1 and uses thereof
CN104497147B (zh) * 2014-12-23 2018-07-03 四川大学 一种双受体识别的串联型穿膜肽修饰的肿瘤靶向纳米递药系统
WO2017126461A1 (ja) 2016-01-19 2017-07-27 国立大学法人徳島大学 がん治療用ペプチド及びそれを含む医薬組成物
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
CN111148752B (zh) 2017-07-19 2024-01-16 国立大学法人德岛大学 肽衍生物和包含其的药物组合物
JP7525855B2 (ja) 2018-11-30 2024-07-31 国立大学法人徳島大学 Ｂｉｇ３－ｐｈｂ２相互作用阻害ｐｈｂ２由来ペプチドを含む乳がん治療薬
CN114773480A (zh) * 2022-06-07 2022-07-22 厦门大学附属翔安医院 一种抗topk第32位丝氨酸残基磷酸化的抗体
CN116082447A (zh) * 2022-09-09 2023-05-09 湖南大学 一种多肽及其制备方法
CN117757789A (zh) * 2022-09-26 2024-03-26 领星生物科技（上海）有限公司 用于抑制肿瘤生长的siRNA及其应用
CN120944846A (zh) * 2025-10-15 2025-11-14 北京索莱宝科技有限公司 人PP1α蛋白及其Thr320位点磷酸化蛋白的抗原肽及其抗体的制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656698B1 (en) * 1999-06-30 2003-12-02 Millennium Pharmaceuticals, Inc. 12832, a novel human kinase-like molecule and uses thereof
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1425410A2 (en) * 2000-10-03 2004-06-09 Glaxo Group Limited Tumor marker and methods of use
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
EP1661986A1 (en) 2000-11-17 2006-05-31 Nuvelo, Inc. Nucleic acids and polypeptides enocoded thereby that are member of the kallikrein gene familyNovel nucleic acids and polypeptides
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003043568A2 (en) 2001-11-15 2003-05-30 The Regents Of The University Of California Compositions and methods for the suppression of mammary epithelial cell proliferation
WO2003064599A2 (en) 2002-01-25 2003-08-07 Origene Technologies, Inc Cancer genes
US6833247B2 (en) * 2002-05-14 2004-12-21 Origene Technologies, Inc. Regulated prostate cancer genes
AU2003217421A1 (en) 2002-02-19 2003-09-09 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
MXPA05001933A (es) 2002-08-19 2005-04-28 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
CA2500982A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
US6971476B2 (en) * 2003-09-05 2005-12-06 D B Industries, Inc. Safety harness
WO2005029067A2 (en) * 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing breast cancer
CN101175862A (zh) * 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
EP2311985A1 (en) 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer
WO2007013575A2 (en) 2005-07-28 2007-02-01 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
PL2201012T3 (pl) * 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
BRPI0919977A2 (pt) * 2008-10-30 2015-08-25 Oncotherapy Science Inc Derivados de 7-hidróxi-benzoimidazol-4-il-metanona e inibidores de pbk contendo os mesmos

Also Published As

Publication number Publication date
WO2008018642A2 (en) 2008-02-14
EP2057187B1 (en) 2016-12-28
SG174071A1 (en) 2011-09-29
JP2010500003A (ja) 2010-01-07
BRPI0716498A2 (pt) 2015-01-27
CA2660438A1 (en) 2008-02-14
EP2057187A2 (en) 2009-05-13
EP2444417A1 (en) 2012-04-25
US20140228238A1 (en) 2014-08-14
US8673548B2 (en) 2014-03-18
US20110135647A1 (en) 2011-06-09
JP5339291B2 (ja) 2013-11-13
WO2008018642A3 (en) 2008-04-03
US9187557B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
EP2057187B1 (en) Genes and polypeptides relating to breast cancers
JP4425141B2 (ja) 非小細胞肺癌の診断のための方法
CN101835894A (zh) Ebi3、dlx5、nptx1和cdkn3用作肺癌治疗和诊断的靶基因
US20110263012A1 (en) Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
JP2010512730A (ja) 肺癌の腫瘍マーカーおよび治療標的としてのｔｔｋ
JP2010501172A (ja) 肺癌に対する予後マーカーおよび治療標的
US20100184047A1 (en) Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
WO2008023841A1 (en) Breast cancer-associated gene, melk, and its interactions with bcl-g
CN101528768A (zh) 与乳腺癌相关的基因和多肽
JP5028601B2 (ja) 乳癌に関連する遺伝子およびポリペプチド
CA2661662A1 (en) Methods of screening for agents that inhibit binding between mphosph1 and prc1
EP2444417B1 (en) Genes and polypeptides relating to breast cancers
JP2013503321A (ja) 乳癌に関連する遺伝子およびポリペプチド
JP2010501162A (ja) 肺癌の治療標的及び予後指標としてのｉｍｐ−１癌遺伝子
JP2011518541A (ja) 癌治療法および癌診断のための標的遺伝子としてのＣ２ｏｒｆ１８
JP2012501166A (ja) 乳癌関連遺伝子ｒｑｃｄ１
JP2012506236A (ja) 抗肺がん化合物または抗食道がん化合物のスクリーニング方法
JP2012501169A (ja) がん関連遺伝子ｌｇｎ／ｇｐｓｍ２

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000